Rifampicin-induced minimal change disease is improved after cessation of rifampicin without steroid therapy

Yonsei Med J. 2015 Mar;56(2):582-5. doi: 10.3349/ymj.2015.56.2.582.

Abstract

There are several reports to demonstrate that rifampicin, a major anti-tuberculosis agent, is associated with some adverse renal effects, with a few cases of rifampicin-induced minimal change disease (MCD). In the present case, a 68-year-old female presented with nausea, vomiting, foamy urine, general weakness and edema. She had been taking rifampicin for 4 weeks due to pleural tuberculosis. The patient had no proteinuria before the anti-tuberculosis agents were started, but urine tests upon admission showed heavy proteinuria with a 24-h urinary protein of 9.2 g/day, and serum creatinine, albumin, and total cholesterol levels were 1.36 mg/dL, 2.40 g/dL, and 283 mg/dL, respectively. MCD was diagnosed, and the patient achieved complete remission after cessation of rifampicin without undergoing steroid therapy.

Keywords: Minimal change disease; rifampicin; steroid.

MeSH terms

  • Aged
  • Antibiotics, Antitubercular / adverse effects*
  • Antibiotics, Antitubercular / therapeutic use
  • Edema / etiology
  • Female
  • Humans
  • Kidney Function Tests
  • Kidney Glomerulus / pathology
  • Nausea / etiology
  • Nephrosis, Lipoid / chemically induced*
  • Nephrosis, Lipoid / pathology
  • Proteinuria
  • Remission Induction
  • Rifampin / adverse effects*
  • Rifampin / therapeutic use
  • Treatment Outcome
  • Tuberculosis, Pleural / drug therapy*

Substances

  • Antibiotics, Antitubercular
  • Rifampin